相关实验视频

Updated: May 17, 2025

A Method for Mouse Pancreatic Islet Isolation and Intracellular cAMP Determination

A Method for Mouse Pancreatic Islet Isolation and Intracellular cAMP Determination

Published on: June 25, 2014

伊卡里因抑制阴茎腔组织中高血糖引起的细胞死亡,并改善1型糖尿病大鼠的勃起功能

Haowei Yang¹, Wenju Xiong¹, Jun Jiang²

¹Department of Urology, the Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, China.

Sexual medicine

|March 31, 2025

概括

伊卡林 (ICA) 治疗减少了1型糖尿病大鼠阴茎组织中的细胞死亡,通过抑制亡,热亡和铁亡来改善勃起功能.

科学领域:

细胞生物学细胞生物学
内分泌学在内分泌学.
药理学药理学是指药理学的学科.

背景情况:

1型糖尿病 (T1DM) 的高血糖导致阴茎组织内皮细胞 (EC) 和光滑肌细胞 (SMC) 死亡,导致勃起功能障碍 (ED).
了解涉及的特定细胞死亡途径 (亡,热亡,铁亡) 对于开发有效的治疗方法至关重要.

研究的目的:

量化T1DM大鼠阴茎腔组织中的阿波普托斯细胞,皮罗普托斯细胞和费罗普托斯细胞.
阐明伊卡林 (ICA) 在T1DM大鼠中改善勃起功能的机制.

主要方法:

在Sprague-Dawley大鼠中使用链毒素 (STZ) 诱导T1DM.
鼠被用ICA (10 mg/kg/d) 或载体治疗了4周.
对阴茎组织进行了细胞死亡标记,氧化应激指标 (ROS,MDA,SOD,GSH) 和勃起功能 (ICPmax/MAP) 的分析.

主要成果:

T1DM显著增加了阿波和铁EC和SMC,以及铁EC.
在T1DM大鼠中,ICA治疗显著降低了这些细胞死亡标志物.
ICA还降低了氧化应激标志物 (ROS) 和增加了抗氧化剂标志物 (GPX4),以及改善勃起功能 (ICPmax/MAP).

结论:

伊卡林通过抑制阴茎洞穴组织中的亡,烧亡和铁亡来缓解T1DM诱导的勃起功能障碍.
这种与减少氧化应激相关的多向细胞死亡抑制,为开发糖尿病相关ED的新疗法提供了基础.

关键词:

灭症 (apoptosis) 是一种死亡的过程.糖尿病糖尿病患者糖尿病患者这是勃起功能障碍.铁性化 (ferroptosis) 是一种艾卡里尼因 (icariin) 是一种热致灭 (pyroptosis) 是一种致的过程.鼠标鼠标鼠标鼠标鼠标

更多相关视频

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

Preparation of Naringenin Solution for In Vivo Application

Preparation of Naringenin Solution for In Vivo Application

Published on: August 10, 2021

相关概念视频

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Diabetes Mellitus: Overview and Type I Subtype

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...